Fractionated initial infusion and booster dose of ARI0002h, a humanised, BCMA-directed CAR T-cell therapy, for patients with relapsed or refractory multiple myeloma (CARTBCMA-HCB-01): a single-arm, multicentre, academic pilot study
Aina Oliver‐Caldés, Verónica González‐Calle, Valentín Cabañas, Marta Español‐Rego, Paula Rodríguez‐Otero, Juan Luis Reguera, Lucía López‐Corral, Beatriz Martín-Antonio, Aintzane Zabaleta, Susana Inogés, Sara Varea, Laura Rosiñol, Ascensión López-Dı́az de Cerio, Natalia Tovar, Raquel Jiménez, Miriam López-Parra, Luis Gerardo Rodríguez‐Lobato, Andrés Sánchez‐Salinas, Eulàlia Olesti, María Calvo‐Orteu, Julio Delgado, José Antonio Pérez‐Simón, Bruno Paiva, Felipe Prósper, Joaquín Sáez‐Peñataro, Manel Juan, José M. Moraleda, María‐Victoria Mateos, Mariona Pascal, Álvaro Urbano-Ispizúa, Carlos Fernández de Larrea
Topics & Concepts
MedicineCytokine release syndromeMultiple myelomaInternal medicineInterim analysisClinical endpointRefractory (planetary science)CAR T-cell therapyLenalidomideChimeric antigen receptorClinical trialOncologyImmunotherapyCancerPhysicsAstrobiologyCAR-T cell therapy researchMultiple Myeloma Research and TreatmentsViral Infectious Diseases and Gene Expression in Insects